GlobeNewswire·Oct 19, 2026, 7:00 AM ET

Parabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026

Parabilis Medicines will present updated Phase 1/2 trial data for zolucatetide in desmoid tumors at the ESMO Congress 2026 in Madrid, Spain, from October 23–27, 2026.
The oral presentation on Saturday, October 24, 2026, at 14:45 CEST covers data from a June 22, 2026 cutoff, including dose escalation & optimization results to inform Phase 3 trial design.
Zolucatetide holds FDA Fast Track & Orphan Drug Designations for the treatment of desmoid tumors.
An investor webcast will be hosted by Parabilis on Saturday, October 24, 2026, at 18:00 CEST to discuss the updated clinical data.
Zolucatetide is a first-in-class direct inhibitor of the β-catenin:TCF interaction, developed using the Helicon™ peptide platform to target undruggable intracellular proteins.
The drug is currently evaluated in a Phase 1/2 trial (NCT05919264) for desmoid tumors, familial adenomatous polyposis, adamantinomatous craniopharyngioma, hepatocellular carcinoma, & other Wnt-driven tumor types.
Desmoid tumors are locally invasive soft-tissue cancers affecting an estimated 30,000 people in the U.S., driven by Wnt/β-catenin pathway mutations with no approved direct therapies.
Parabilis is also advancing a follow-on β-catenin degrader program & additional Helicon-based programs targeting ERG & allosteric AR ON in prostate cancer.
The press release includes forward-looking statements regarding trial expectations, dose selection, & potential efficacy, noting risks that actual results may differ materially.